Hepatitis C Therapeutics in Asia-Pacific Markets to 2023-Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

ReportsWeb.com published “Hepatitis C Therapeutics Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Original Content:

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distribution. Acute HCV infection is usually asymptomatic, and 15-45% of people spontaneously clear the virus within six months of infection without any treatment, while the remaining 55-85% develop chronic HCV infection.

For more information about this report: http://www.reportsweb.com/hepatitis-c-therapeutics-in-asia-pacific-markets-to-2023

The hepatitis C market is currently dominated by high-performance regimens comprising new-generation DAAs. The treatment algorithms have shifted away rapidly from interferon-based therapies, and towards interferon-free DAA combination therapies that can cure most patients in as little as eight to 12 weeks, without ribavirin. In the highly competitive hepatitis C treatment landscape, where new combination therapies match each other closely in terms of safety and efficacy, one key differential is patient segment coverage. A number of factors that have conventionally been used to predict treatment outcome, including HCV genotypes, previous treatment history, and a patient's liver and kidney conditions, are also used to define target patient populations for new therapies.

Scope

The hepatitis C Asia-Pacific market will be valued at $8.31 billion in 2023, growing from $5.38 billion in 2016 at a CAGR of 6.4%.
-How will pan-genotypic therapies such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir contribute to growth-
-What effect will the patent expiration of branded therapies have on market value-
The hepatitis C pipeline contains a range of molecule types and molecular targets, including those that are well established in hepatitis C, and novel target therapies.
-What are the common targets and mechanisms of action of pipeline therapies-
-Will the pipeline therapies fulfill the unmet needs of the hepatitis C market-
-What implications will the increased focus on pan-genotypic therapies have on the future of hepatitis C treatment-
Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
-How have the late-stage therapies performed in clinical trials-
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011030776/sample
Reasons to buy

-Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
-Visualize the composition of the hepatitis C market in terms of dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
-Analyze the hepatitis C pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
-Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
-Predict hepatitis C market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
-Identify commercial opportunities in the hepatitis C deals landscape by analyzing trends in licensing and co-development deals.
Companies Mentioned:
Integra LifeSciences Holdings Corp
Medtronic Plc
DePuy Synthes Inc
B. Braun Melsungen AG
Inquire for Report at http://www.reportsweb.com/buy&RW00011030776/buy/4995
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Pune:
505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.